entertainment -WSS

entertainment

author：knowledge 2025-09-30 20:35:46 - browse：36

Monica Bertagnolli -- Health Policy coverage from STAT — Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： UnitedHealth’s Optum accused of antitrust violations in California

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

Senate panel clears PBM, hopsital reforms

What to do when lifesaving products contribute to climate change

Takeda, Janssen join wearable maker to measure scratching

STAT Executive Editor Rick Berke on STAT's 8th birthday

Free speech concerns arise in wake of journal editor Eisen's firing

hotspot

entertainment

Sign up for D.C. Diagnosis

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

At least 13 dead in Texas as scorching temps continue

Mayo Clinic plans $5B tech

Moonlake's readout produced a cash windfall. Risks remain

Will General Catalyst be the first of many hospital takeovers?

The cancer drug shortage isn’t new — and neither are the solutions

FDA approves potent Eli Lilly obesity drug, Zepbound

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Pediatric cancer treatments threatened by a new FDA policy

knowledge

The EPA's new lead rule: How one expert crunched the numbers

Medicare solvency divides Republicans at the presidential debate

STAT Executive Editor Rick Berke on STAT's 8th birthday

HPV cancer vaccine study demonstrates efficacy

UCSF medical school apologizes for unethical prisoner experiments

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

explore

leisure time

hotspot

hotspot